Pharma pushes for GLP-1 receptor agonist to be listed on the PBS for obesity
Eli Lilly says it plans to apply to the PBAC this year.
Pharmaceutical giant Eli Lilly is readying a PBAC application for tirzepatide, which if successful, would become the first GLP-1 receptor agonist publicly funded for obesity treatment.
Without giving a dollar figure, the company has acknowledged that a listing would be expensive for taxpayers but says the downstream effects will be worth it.
